{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:01:38Z","timestamp":1746504098088,"version":"3.40.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.mehy.2014.09.015","type":"journal-article","created":{"date-parts":[[2014,10,19]],"date-time":"2014-10-19T12:33:24Z","timestamp":1413722004000},"page":"673-676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Potential use of Magnolia officinalis bark polyphenols in the treatment of cannabis dependence"],"prefix":"10.1016","volume":"83","author":[{"given":"Maurizio","family":"Coppola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Mondola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2014.09.015_b0005","unstructured":"United Nations Office on Drugs and Crime. World Drug Report 2014. United Nations publication 2014. Available at: <https:\/\/www.unodc.org\/documents\/wdr2014\/World_Drug_Report_2014_web.pdf> (visited August 20, 2014)."},{"key":"10.1016\/j.mehy.2014.09.015_b0010","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Cannabis problems in context: understanding the increase in European treatment demands. European Monitoring Centre for Drugs and Drug Addiction 2004. Available at: <http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_37361_EN_sel2004_2-en.pdf> (visited August 20, 2014)."},{"key":"10.1016\/j.mehy.2014.09.015_b0015","doi-asserted-by":"crossref","first-page":"e18627","DOI":"10.5812\/ijhrba.18627","article-title":"Cannabis consumption systemic adverse effects","volume":"3","author":"Coppola","year":"2014","journal-title":"Int J High Risk Behav Addict"},{"key":"10.1016\/j.mehy.2014.09.015_b0020","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.psc.2012.03.003","article-title":"State of the art treatments for cannabis dependence","volume":"35","author":"Danovitch","year":"2012","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.mehy.2014.09.015_b0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.mehy.2013.07.016","article-title":"Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence","volume":"81","author":"Coppola","year":"2013","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2014.09.015_b0030","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.3390\/molecules15096452","article-title":"Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders","volume":"15","author":"Shen","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.mehy.2014.09.015_b0035","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pharmthera.2011.01.010","article-title":"Therapeutic applications of compounds in the Magnolia family","volume":"130","author":"Lee","year":"2011","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2014.09.015_b0040","unstructured":"PubChem Project. Magnolol. 2014. Available at: <https:\/\/pubchem.ncbi.nlm.nih.gov\/summary\/summary.cgi?cid=72300&loc=ec_rcs> (visited August 22, 2014)."},{"key":"10.1016\/j.mehy.2014.09.015_b0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.2042-7158.1996.tb05877.x","article-title":"Pharmacokinetics and brain distribution of magnolol in the rat after intravenous bolus injection","volume":"48","author":"Tsai","year":"1996","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.mehy.2014.09.015_b0050","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0090-9556(25)07508-7","article-title":"Disposition of magnolol after intravenous bolus and infusion in rabbits","volume":"22","author":"Tsai","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.mehy.2014.09.015_b0055","unstructured":"PubChem Project. Honokiol. 2014. Available at: <https:\/\/pubchem.ncbi.nlm.nih.gov\/summary\/summary.cgi?cid=72303&loc=ec_rcs> (visited August 25, 2014)."},{"key":"10.1016\/j.mehy.2014.09.015_b0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0378-4347(94)00031-X","article-title":"Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography","volume":"655","author":"Tsai","year":"1994","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.mehy.2014.09.015_b0065","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.3748\/wjg.v10.i23.3459","article-title":"Honokiol: a potent chemotherapy candidate for human colorectal carcinoma","volume":"10","author":"Chen","year":"2004","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mehy.2014.09.015_b0070","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1002\/jps.22536","article-title":"In vitro metabolism and disposition of honokiol in rat and human livers","volume":"100","author":"B\u00f6hmdorfer","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.mehy.2014.09.015_b0075","unstructured":"In the same study, authors investigated the metabolic stability of 4-O-methylhonokiol in rat liver microsomes and cytosol. This study evidenced that, in the presence of NADPH, 4-Omethylhonokiol was metabolized in honokiol via oxidative O-demethylation by cytochrome P450."},{"key":"10.1016\/j.mehy.2014.09.015_b0080","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0163-7258(97)82001-3","article-title":"Pharmacology of cannabinoid CB1 and CB2 receptors","volume":"74","author":"Pertwee","year":"1997","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.mehy.2014.09.015_b0085","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.bjp.0705931","article-title":"Marijuana and cannabinoid regulation of brain reward circuits","volume":"143","author":"Lupica","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2014.09.015_b0090","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.mehy.2014.09.015_b0095","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.neuropharm.2009.07.017","article-title":"Functional CB2 type cannabinoid receptors at CNS synapses","volume":"57","author":"Morgan","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mehy.2014.09.015_b0100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/ml300235q","article-title":"Magnolia extract, magnolol, and metabolites: activation of cannabinoid CB2 receptors and blockade of the related GPR55","volume":"4","author":"Rempel","year":"2012","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.mehy.2014.09.015_b0105","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.chembiol.2011.05.012","article-title":"Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists","volume":"18","author":"Schuehly","year":"2011","journal-title":"Chem Biol"},{"key":"10.1016\/j.mehy.2014.09.015_b0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0040-4039(01)87494-3","article-title":"Cannabidivarin, a new hashish constituent","volume":"3","author":"Vollner","year":"1969","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.mehy.2014.09.015_b0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0169-328X(98)00277-0","article-title":"Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain","volume":"64","author":"Sawzdargo","year":"1999","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.mehy.2014.09.015_b0120","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.mehy.2014.09.015_b0125","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1073\/pnas.1211204110","article-title":"Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses","volume":"110","author":"Sylantyev","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2014.09.015_b0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2005.03.027","article-title":"Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies","volume":"80","author":"Hart","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mehy.2014.09.015_b0135","doi-asserted-by":"crossref","first-page":"e77739","DOI":"10.1371\/journal.pone.0077739","article-title":"The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists","volume":"8","author":"Fuchs","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714003405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714003405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T06:32:12Z","timestamp":1746426732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987714003405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0306987714003405"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2014.09.015","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential use of Magnolia officinalis bark polyphenols in the treatment of cannabis dependence","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2014.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}